Amfil Technologies (AMFE) 0.0080 $AMFE
Easton Pharmaceuticals Inc. Suspends All Potentially Dilutive Financing as a Direct Result of Negotiations With a Major California Based Medical Marijuana Grow-Op
Marketwired - Mon Dec 22, 7:01AM CST
Easton Pharmaceuticals Inc. (OTC PINK: EAPH) announces it has suspended all types of financings considered more dilutionary compared to other financing options currently available.
Novus MedPlan Cost-Saving Provider Network Offers A Strong Value Proposition
ACCESSWIRE - Fri Nov 07, 8:01AM CST
WHITEFISH, MT / ACCESSWIRE / November 7, 2014 / Marijuana reform was a key ballot initiative in seven states (as well as 17 municipalities and D.C.) this week, with more drug policy reform questions (most aimed at reforming or out outright repealing marijuana laws) on the ballot than at any time in the history of the country. In California, Proposition 47 was passed, transforming the lowest-level non-violent crimes like simple drug possession, from a felony to a misdemeanor, freeing up an estimated $1B per annum to be dedicated to useful things like crime prevention, school funding, mental health treatment, and victim services. Regulatory reforms like this are opening up sizable markets for both private and public sector participants.
GWPH: 78.09 (+1.70)
Easton Pharmaceuticals Provides AMFIL Update on the mPact - GROzone Antimicrobial System
Marketwire - Tue Sep 23, 11:26AM CDT
Easton Pharmaceuticals Inc. (OTC: EAPH) announces update on the mPact - GROzone Antimicrobial System through its investment and ownership interest in AMFIL Technologies.
Amfil Technologies Inc. Provides Shareholder Update
ACCESSWIRE - Tue Aug 19, 1:21PM CDT
TORONTO, ON / ACCESSWIRE / August 19, 2014 / Amfil Technologies Inc. (OTC Pink: AMFE) (PINKSHEETS) is pleased to announce that the company accountants and auditing team at MNP LLC. are now working on the audited financial statements for the most recent year ended June 30th 2014. The company expects to file audited financial statements within the next two to three weeks if progress continues as expected. The most economical approach for the company and its shareholders is to include the most recent 10k in the upcoming filings that will be submitted as having MNP complete an audit review on the three quarters following the June 30th 2013 10k and a standalone 2014 year end audit would be significantly more costly to the company than the approach we have decided to take. We appreciate the patience of our shareholders as we finalize this process. The company looks forward to completing the audit and continuing the successful execution of the new business plan.
Easton Pharmaceuticals Provides Update on mPACT-Grozone 60(TM) and Other Corporate Initiatives
Marketwire - Wed Jul 16, 11:59AM CDT
Easton Pharmaceuticals Inc. (OTC: EAPH) - Announces It is scheduled at the end of July to participate with Amfil Technologies Inc. in the introduction of the first mPACT-Grozone 60(TM) unit.
Easton Pharmaceuticals Inc. Suspends All Potentially Dilutive Financing as a Direct Result of Negotiations With a Major California Based Medical Marijuana Grow-Op
Marketwired - Mon Dec 22, 7:01AM CST
Easton Pharmaceuticals Inc. (OTC PINK: EAPH) announces it has suspended all types of financings considered more dilutionary compared to other financing options currently available.
Novus MedPlan Cost-Saving Provider Network Offers A Strong Value Proposition
ACCESSWIRE - Fri Nov 07, 8:01AM CST
WHITEFISH, MT / ACCESSWIRE / November 7, 2014 / Marijuana reform was a key ballot initiative in seven states (as well as 17 municipalities and D.C.) this week, with more drug policy reform questions (most aimed at reforming or out outright repealing marijuana laws) on the ballot than at any time in the history of the country. In California, Proposition 47 was passed, transforming the lowest-level non-violent crimes like simple drug possession, from a felony to a misdemeanor, freeing up an estimated $1B per annum to be dedicated to useful things like crime prevention, school funding, mental health treatment, and victim services. Regulatory reforms like this are opening up sizable markets for both private and public sector participants.
GWPH: 78.09 (+1.70)
Easton Pharmaceuticals Provides AMFIL Update on the mPact - GROzone Antimicrobial System
Marketwire - Tue Sep 23, 11:26AM CDT
Easton Pharmaceuticals Inc. (OTC: EAPH) announces update on the mPact - GROzone Antimicrobial System through its investment and ownership interest in AMFIL Technologies.
Amfil Technologies Inc. Provides Shareholder Update
ACCESSWIRE - Tue Aug 19, 1:21PM CDT
TORONTO, ON / ACCESSWIRE / August 19, 2014 / Amfil Technologies Inc. (OTC Pink: AMFE) (PINKSHEETS) is pleased to announce that the company accountants and auditing team at MNP LLC. are now working on the audited financial statements for the most recent year ended June 30th 2014. The company expects to file audited financial statements within the next two to three weeks if progress continues as expected. The most economical approach for the company and its shareholders is to include the most recent 10k in the upcoming filings that will be submitted as having MNP complete an audit review on the three quarters following the June 30th 2013 10k and a standalone 2014 year end audit would be significantly more costly to the company than the approach we have decided to take. We appreciate the patience of our shareholders as we finalize this process. The company looks forward to completing the audit and continuing the successful execution of the new business plan.
Easton Pharmaceuticals Provides Update on mPACT-Grozone 60(TM) and Other Corporate Initiatives
Marketwire - Wed Jul 16, 11:59AM CDT
Easton Pharmaceuticals Inc. (OTC: EAPH) - Announces It is scheduled at the end of July to participate with Amfil Technologies Inc. in the introduction of the first mPACT-Grozone 60(TM) unit.
